Imugene Future Growth

Future criteria checks 3/6

Imugene is forecast to grow earnings and revenue by 51.3% and 66.6% per annum respectively. EPS is expected to grow by 55.2% per annum. Return on equity is forecast to be -63.5% in 3 years.

Key information

51.3%

Earnings growth rate

55.2%

EPS growth rate

Biotechs earnings growth	16.1%
Revenue growth rate	66.6%
Future return on equity	-63.5%
Analyst coverage	Low
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:IMU - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	44	-69	-34	-34	2
6/30/2025	N/A	-100	-54	-54	2
6/30/2024	N/A	-116	-85	-85	2
12/31/2023	15	-89	-73	-61	N/A
9/30/2023	13	-64	-52	-46	N/A
6/30/2023	12	-38	-31	-31	N/A
3/31/2023	12	-39	-37	-37	N/A
12/31/2022	12	-40	-42	-42	N/A
9/30/2022	13	-39	-36	-36	N/A
6/30/2022	13	-38	-31	-31	N/A
3/31/2022	11	-33	-27	-25	N/A
12/31/2021	8	-27	-24	-20	N/A
9/30/2021	8	-23	-21	-16	N/A
6/30/2021	7	-18	-19	-13	N/A
3/31/2021	7	-15	-16	-12	N/A
12/31/2020	6	-12	-12	-11	N/A
9/30/2020	5	-11	-12	-11	N/A
6/30/2020	4	-11	-12	-10	N/A
3/31/2020	5	-10	-11	-10	N/A
12/31/2019	5	-9	-10	-9	N/A
9/30/2019	5	-8	-9	-8	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	-7	-7	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	2	-5	-6	-5	N/A
6/30/2018	2	-4	-5	-5	N/A
3/31/2018	1	-3	-4	-4	N/A
12/31/2017	1	-3	-3	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	2	-3	N/A	-3	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-2	N/A	-2	N/A
9/30/2015	1	-2	N/A	-2	N/A
6/30/2015	1	-2	N/A	-2	N/A
3/31/2015	1	-2	N/A	-2	N/A
12/31/2014	1	-2	N/A	-2	N/A
9/30/2014	1	-2	N/A	-1	N/A
6/30/2014	1	-2	N/A	-1	N/A
3/31/2014	0	-2	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: IMU is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IMU is expected to become profitable in the next 3 years.

Revenue vs Market: IMU is forecast to have no revenue next year.

High Growth Revenue: IMU is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMU is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Imugene Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Imugene Limited, Annual General Meeting, Nov 30, 2023

No longer forecast to breakeven

New minor risk - Share price stability

Less than half of directors are independent

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

Independent Non-Executive Director recently sold AU$1.2m worth of stock

Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 0.324115 million.

Revenue in line with expectations

Imugene Limited Commences Cohort 2 Dosing in Phase 1 PD1-Vaxx Trial

Imugene Limited Dose Escalates in Phase I Clinical Trial of New Checkpoint Immunotherapy PD1-VAXX

Imugene Limited Completes Recruitment to HER-Vaxx Phase 2 Trialim

Imugene Limited Completes Enrolment of First Cohort in Phase I Clinical Trial of New Checkpoint Immunotherapy PD1-Vaxx

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies